Archive | December, 2009
Enzo Biochem Signs Marketing Agreement (NYSE:ENZ)
Enzo Biochem Inc (NYSE:ENZ) has announced that they have signed an exclusive marketing deal with privately owned Ikonisys Inc of New Haven, CT.
Continue reading...GTx Announces Reduction in Workforce (NASDAQ:GTXI)
15 December 2009 – 7:15 am PST
Comments Off
GTx, Inc (NASDAQ:GTXI) has announced that they will be reducing their workforce due to delay in the potential commercialization of toremifene 80 mg that reduces fractures in men with prostrate cancer on androgen deprivation therapy (ADT).
Continue reading...BioMimetic Ships Augment Bone Graft (NASDAQ:BMTI)
15 December 2009 – 7:00 am PST
Comments Off
BioMimetic Therapeutics Inc (NASDAQ:BMTI) has announced that they have shipped their first order of Augment Bone Graft to their Canadian distributor, Joint Solutions Alliance Corporation.
Continue reading...Ameritrade restricts trading of BIEL and HTDS
14 December 2009 – 10:37 am PST
Recently, I have been conducting some detailed analysis on Bioelectronics Corp ( OTC:BIEL) and HARD TO TREAT DISEASES (PINK:HTDS) . I went to a great length to unravel the potential of rising in price of BIEL and HTDS over the next few months. On BIEL, in particular, I found the stock to be of excellent [...]
Continue reading...Fero Industries’ Growth Strategy (OTC:FROI)
10 December 2009 – 6:45 am PST
Comments Off
Fero Industries, Inc (OTC:FROI) has announced their growth strategy publicly where they have disclose about Fero Industries first acquisition target which is Pyro Pharmaceuticals.
Continue reading...Medifocus Begins OTC Trading (OTC:MDFZE)
10 December 2009 – 6:30 am PST
Comments Off
Medifocus, Inc (OTC:MDFZE) has announced that they have begun trading their common stock on the over the counter (OTC) pink sheets market from Dec. 7, 2009.
Continue reading...Neoprobe Submits Phase 3 Data to FDA (OTC:NEOP)
9 December 2009 – 6:30 am PST
Comments Off
Neoprobe Corporation (OTC:NEOP) has announced that they have completed their Phase 3 clinical trial of Lmyphoseek (NEO3-35) with positive results and that they have submitted the data to US Food and Drug Administration to discuss the results of the clinical trial as part of our continuing preparation of a New Drug Application (NDA), which they [...]
Continue reading...Quidel’s Stock Repurchase Program (NASDAQ:QDEL)
9 December 2009 – 6:15 am PST
Comments Off
Quidel Corporation (NASDAQ:QDEL) has announced that their Board of Directors have authorized for an extension of the Company’s current common stock repurchase program.
Continue reading...Allos Provides New Folotyn Data (NASDAQ:ALTH)
8 December 2009 – 7:45 am PST
Comments Off
Allos Therapeutics Inc (NASDAQ:ALTH) has reported a new analysis of data from the pivotal PROPEL trial of FOLOTYN in patients who are suffering from relapsed and refractory peripheral T-cell lymphoma (PTCL).
Continue reading...Facet Biotech Reports Elotuzumab Data (NASDAQ:FACT)
8 December 2009 – 7:30 am PST
Comments Off
Facet Biotech Corporation (NASDAQ:FACT) along with Bristol-Myers Squibb Company have announced that the interim data from the study of elotuzumab is promising.
Continue reading...
15 December 2009 – 7:30 am PST
Comments Off